Building Safer CRISPR Medicines for CVD with Scribe Therapeutics' Benjamin Oakes

We love to hear from our listeners. Send us a message. In episode 121 of Cell & Gene: The Podcast, Host Erin Harris talks to Scribe Therapeutics' CEO and Co-Founder Benjamin Oakes about building next‑generation CRISPR and epigenetic editing tools to move genetic medicine beyond rare disease into common cardiometabolic indications. Oakes shares Scribe’s engineered CasX platform and epigenetic silencers, preclinical data from its various programs, and why exquisite specificity and low-dose LNP delivery are essential to treating patients safely. They also explore Scribe’s partnerships with Sanofi and Lilly, the company’s cardiometabolic-first strategy co-developed with Dr. Jennifer Doudna, and Oakes’ conviction that genetic medicines can fundamentally reshape healthspan and the future of preventive cardiovascular care.

You can listen to Building Safer CRISPR Medicines for CVD with Scribe Therapeutics' Benjamin Oakes online on Radio and Podcast. Open the player on this page to stream the available audio.

Building Safer CRISPR Medicines for CVD with Scribe Therapeutics' Benjamin Oakes is an episode from Cell & Gene: The Podcast by Erin Harris.

This episode is 30:03 long.

This episode was published on Jan 29, 2026.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from Cell & Gene: The Podcast when more episodes are available from the podcast feed.